Related Experiment Video
Updated: Feb 18, 2026
Differentiation of Human Pluripotent Stem Cells Into Pancreatic Beta-Cell Precursors in a 2D Culture System
Published on: December 16, 2021
Regenerating β cells of the pancreas - potential developments in diabetes treatment
1a Department of Biochemistry & Molecular Biology , Louisiana State University Health Science Center , New Orleans , LA , USA.
Introduction:
The etiology of diabetes is mainly attributed to insulin deficiency due to the lack of β cells (type 1), or to insulin resistance that eventually results in β cell dysfunction (type 2). Therefore, an ultimate cure for diabetes requires the ability to replace the lost insulin-secreting β cells. Strategies for regenerating β cells are under extensive investigation.
Areas Covered:
Herein, the authors first summarize the mechanisms underlying embryonic β cell development and spontaneous adult β cell regeneration, which forms the basis for developing β cell regeneration strategies. Then the rationale and progress of each β cell regeneration strategy is reviewed. Current β cell regeneration strategies can be classified into two main categories: in vitro β cell regeneration using pluripotent stem cells and in vivo reprogramming of non-β cells into β cells. Each has its own advantages and disadvantages.
Expert Opinion:
Regenerating β cells has shown its potential as a cure for the treatment of insulin-deficient diabetes. Much progress has been made, and β cell regeneration therapy is getting closer to a clinical reality. Nevertheless, more hurdles need to be overcome before any of the strategies suggested can be fully translated from bench to bedside.
Insights
Replacing lost insulin-producing beta cells is key to curing diabetes. Research explores strategies like stem cell therapy and cell reprogramming for beta cell regeneration, moving closer to clinical application.
Area of Science:
- Endocrinology and Regenerative Medicine
- Stem Cell Biology
- Diabetes Research
Background:
- Diabetes mellitus (type 1 and type 2) is characterized by insulin deficiency or resistance, stemming from a loss or dysfunction of pancreatic beta cells.
- Restoring functional beta cell mass is a primary goal for achieving a definitive cure for diabetes.
- Understanding embryonic beta cell development and adult beta cell regeneration mechanisms is crucial for developing therapeutic strategies.
Purpose of the Study:
- To review and summarize current strategies for beta cell regeneration.
- To analyze the progress, advantages, and disadvantages of different beta cell regeneration approaches.
- To provide an expert opinion on the clinical translation of beta cell regeneration therapies.
Main Methods:
- Review of scientific literature on embryonic beta cell development and adult beta cell regeneration.
- Classification and analysis of current beta cell regeneration strategies.
- Discussion of in vitro regeneration using pluripotent stem cells and in vivo reprogramming of non-beta cells.
Main Results:
- Beta cell regeneration strategies are broadly categorized into in vitro methods using pluripotent stem cells and in vivo reprogramming of existing cells.
- Both approaches have demonstrated potential but also present distinct challenges and limitations.
- Significant progress has been made in the field, indicating that beta cell regeneration therapy is approaching clinical feasibility.
Conclusions:
- Beta cell regeneration holds promise as a curative treatment for insulin-deficient diabetes.
- While considerable advancements have been achieved, further research is necessary to overcome existing hurdles.
- Successful translation of beta cell regeneration strategies from laboratory research to clinical practice requires addressing remaining challenges.
Related Concept Videos
01:25Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
01:23Tissue Renewal without Stem Cells
However, failure of such a system...
01:22iPS Cell Differentiation
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...